Search

The authors studied comparatively a number of indices of nonspecific immune protection in 32 patients with paraneoplasia, in 34 patients with malignant (19) and benign (15) skin neoplasms, and also in 20 healthy persons. It has been found that in patients with paraneoplasias and skin cancer the most sensitive tests for decreased immune responses are as follows: qualitative and quantitative changes in the autoflora of non-involved skin covers, lysozyme titre and general bactericidity of blood serum. A progressive increase of dissemination of the skin cover against the background of the reduced lysozyme titre and general bactericidity of blood serum and also the appearance of C-reactive protein in serum render it reasonable to suspect malignant tumor process in patients suffering eczema, psoriasis and other skin lesions.

Under study were the factors of antitumor immunity (RHDT, the reaction of microprecipitation, the functional activity of lymphocytes, RFC and RBT) in 104 patients with cancer of the corpus uteri. It was found that most patients show an impaired immunobiological response, manifested in higher percentage of positive results with RHDT performed with the tumor antigen, and the reaction of microprecipitation with tumor and embryonal antigens, more week RFC and RBT. Immunological indices are getting worse with the process spread and are improved following the combination therapy. The process of treatment however (surgery and radiotherapy) renders a negative effect on immune indices. Normalization of the latter is noted not earlier than 1-3 years after the treatment.

Under study were immunological indices--the reaction of microprecipitation (tumor and embryonal antigens) and HRDT (tumor and tuberculine antigens) in 305 patients with cancer of the uterine cervix. It was found that most patients showed impaired immune responses: an increased number of persons with specific antibodies circulating in blood serum and increased hypersensitivity of of delayed type. The percentage of positive reactions of microprecipitation and HRDT increases as the tumor spreads. The methods of combined therapy generally improve immunological indices, however, the process starts 1-3 years following the treatment.